Copy

Click here if you cannot read this message

  Press Release 3 June 2016  
 
 
 

Bone Therapeutics celebrates ten years of innovation in bone cell therapy

Gosselies, Belgium, 3 June 2016 - BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in the fields of bone fracture repair, fracture prevention and spinal fusion, today celebrates its ten-year anniversary with an evening event which will bring together guests from industry, government and the media as well as representatives of the international scientific community. The event will be attended by Mr Paul Magnette, Minister-President of Wallonia and Mr Jean-Claude Marcourt, Vice-President and Minister of Economy, Industry, Innovation and New Technologies of the Walloon Government.

Enrico Bastianelli, CEO of Bone Therapeutics commented: "We are proud of what we have achieved in the ten years since Bone Therapeutics was founded in 2006. We have come a long way, with two products in the clinic, six clinical trials and preparations underway to initiate trials in the US. We are grateful for the support of our investors, as well as the Walloon Government, without whom this would not have been possible. We want to mark this ten-year milestone in the company’s history, and look forward to the next ten years of progress."

Paul Magnette, Minister-President of Wallonia and Mayor of Charleroi said: "Bone Therapeutics is a great example of how dynamic, high technology companies enhance the economy and social fabric of Wallonia, creating employment and bringing innovation to the region. Wallonia has established a leadership position in the field of cell therapy in part through the achievements of companies like Bone Therapeutics and their contributions to this endeavour."

Jean-Claude Marcourt, Vice-President and Minister of Economy, Industry, Innovation and New Technologies of the Walloon Government, adds: "Over the past decade, Wallonia has seen its biotechnology industry grow significantly and it is now at the forefront in the field of cell therapy. An important contributory factor was the creation of Biowin, the health cluster of Wallonia. This initiative, which has a broad international reach, creates the perfect ecosystem for emerging biotech companies to thrive. The Walloon region has supported and keeps on supporting innovative ventures, like Bone Therapeutics, that strengthen its position."

Since its foundation in 2006 as a spin-off from the Université Libre de Bruxelles (ULB: Brussels, Belgium), Bone Therapeutics has focused on developing a technology initiated at the Erasme Hospital of the ULB. The Company has built on these initial foundations and is now running clinical trials in six indications. With the support of its shareholders and the Walloon Region, the Company has grown significantly over the past ten years, employing over 100 people, and has established its position as a leader in the field of bone cell therapy.

 
 
 
 
 

To read this press release in French or Dutch, please follow the link below:
FR - NL

 
 

 
 

For further information, please contact:

Bone Therapeutics SA

Enrico Bastianelli, Chief Executive Officer
Wim Goemaere, Chief Financial Officer
Tel: +32 (0)2 529 59 90
investorrelations@bonetherapeutics.com

For Belgium and International Media Enquiries
Consilium Strategic Communications

Amber Fennell, Jessica Hodgson and Hendrik Thys
Tel: +44 (0) 20 3709 5701
bonetherapeutics@consilium-comms.com
 

For French Media and Investor Enquiries
NewCap Investor Relations & Financial Communications

Pierre Laurent, Louis-Victor Delouvrier and Nicolas Merigeau
Tel: + 33 (0)1 44 71 94 94
bone@newcap.eu

 

 
 

 
 
Follow us

Click here to unsubscribe
 
 

 
         Fond Européen

Le Fonds européen de développement régional et la Wallonie investissent dans votre avenir.

 
 
 
 

About Bone Therapeutics

Bone Therapeutics is a leading biotechnology company specializing in the development of cell therapy products intended for bone fracture repair, fracture prevention and spinal fusion. The current standard-of-care in this field involves major surgeries and long recovery periods. To overcome these problems, Bone Therapeutics is developing a range of innovative regenerative products containing osteoblastic/bone-forming cells, administrable via a minimally invasive percutaneous technique; a unique proposition in the market.
PREOB®, Bone Therapeutics’ autologous bone cell product, is currently in pivotal Phase IIB/III clinical studies for two indications: osteonecrosis and non-union fractures, and in Phase II for severe osteoporosis. ALLOB®, its allogeneic “off-the-shelf” bone cell product, is in Phase II for the treatment of delayed-union fractures and spinal fusion procedures. The Company also runs preclinical research programs and develops novel product candidates.
Founded in 2006, Bone Therapeutics is headquartered in Gosselies (South of Brussels, Belgium). Bone Therapeutics’ regenerative products are manufactured to the highest GMP standards and are protected by a rich IP estate covering 11 patent families. Further information is available at www.bonetherapeutics.com.


Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

 
Bone Therapeutics S.A. • Rue Auguste Piccard, 37 • 6041 Gosselies • Belgium (Europe) • Phone: +32 (0) 2 529 59 90 • Fax: +32 (0) 2 529 59 93 • www.bonetherapeutics.com